Literature DB >> 19712272

Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis.

Katsutoshi Tokushige1, Etsuko Hashimoto, Haruka Noto, Satoru Yatsuji, Maki Tobari, Nobuyuki Torii, Makiko Taniai, Keiko Shiratori, Hiroshi Murayama.   

Abstract

AIM: Ornithine carbamoyltransferase (OCT) is reported to be a liver-specific marker for the evaluation of hapatocellular damage. In this study, we investigated its clinical significance in non-alcoholic steatohepatitis (NASH).
METHODS: Serum OCT levels were measured by the ELISA (enzyme-linked immunosorbent assay) method. One hundred and twenty patients with NASH (18 liver cirrhosis induced by NASH and 9 NASH combined with hepatocellular carcinoma) were measured.
RESULTS: The serum levels of OCT and the ratios of OCT : alanine amino transferase (ALT) and OCT : aspartate amino transferase (AST) were increased in parallel with the progression of NASH. Especially, OCT and both ratios were markedly increased in hepatocellular carcinoma. As for the relationship between fibrosis grade and OCT, the serum OCT levels and the ratio of OCT : ALT levels were increased in parallel with liver fibrosis. In NASH patients with ALT within normal range, about 30% showed elevation of OCT.
CONCLUSION: Serum OCT levels and the ratios of OCT : ALT and OCT : AST increase in parallel with the progression of NASH. It was suggested that OCT is a useful marker in the progression of NASH.

Entities:  

Year:  2009        PMID: 19712272     DOI: 10.1111/j.1872-034X.2009.00530.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  1 in total

1.  Involvement of Ornithine Carbamoyltransferase in the Progression of Chronic Hepatitis C and Liver Cirrhosis.

Authors:  Masahiko Ohnishi; Akihisa Higuchi; Hiroshi Matsumura; Yasuo Arakawa; Hitomi Nakamura; Kazushige Nirei; Toshiki Yamamoto; Hiroaki Yamagami; Masahiro Ogawa; Takuji Gotoda; Shunichi Matsuoka; Noriko Nakajima; Masahiko Sugitani; Mitsuhiko Moriyama; Hiroshi Murayama
Journal:  Int J Med Sci       Date:  2017-06-14       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.